WO2009108857A3 - Combination therapy for prostate cancer - Google Patents

Combination therapy for prostate cancer Download PDF

Info

Publication number
WO2009108857A3
WO2009108857A3 PCT/US2009/035464 US2009035464W WO2009108857A3 WO 2009108857 A3 WO2009108857 A3 WO 2009108857A3 US 2009035464 W US2009035464 W US 2009035464W WO 2009108857 A3 WO2009108857 A3 WO 2009108857A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate cancer
combination therapy
inhibitors
combination
hdac inhibitors
Prior art date
Application number
PCT/US2009/035464
Other languages
French (fr)
Other versions
WO2009108857A2 (en
Inventor
Peter Kushner
Cyrus Harmon
Leslie Hodges-Gallagher
William Stafford
Original Assignee
Combithera, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combithera, Inc. filed Critical Combithera, Inc.
Publication of WO2009108857A2 publication Critical patent/WO2009108857A2/en
Publication of WO2009108857A3 publication Critical patent/WO2009108857A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines

Abstract

The present application demonstrates that HDAC inhibitors can be used in combination with IGF-1R inhibitors and mTOR inhibitors to treat prostate cancer. Combinations of the compounds, with or without HDAC inhibitors, and with or without androgen ablation therapy, can also be used, if indicated. The invention therefore provides methods of treatment and pharmaceutical compositions.
PCT/US2009/035464 2008-02-27 2009-02-27 Combination therapy for prostate cancer WO2009108857A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3190308P 2008-02-27 2008-02-27
US61/031,903 2008-02-27
US3393108P 2008-03-05 2008-03-05
US61/033,931 2008-03-05

Publications (2)

Publication Number Publication Date
WO2009108857A2 WO2009108857A2 (en) 2009-09-03
WO2009108857A3 true WO2009108857A3 (en) 2010-01-14

Family

ID=41016726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/035464 WO2009108857A2 (en) 2008-02-27 2009-02-27 Combination therapy for prostate cancer

Country Status (1)

Country Link
WO (1) WO2009108857A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280112A1 (en) * 2008-05-05 2009-11-12 The Regents Of The University Of California Inhibitory effects of nordihydroguaiaretic acid (ndga) on the igf-1 receptor and androgen dependent growth of lapc-4 prostate cancer cells
GB0811992D0 (en) * 2008-07-01 2008-08-06 Mithen Richard Treatment
CA2941010A1 (en) 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy
CN104117064B (en) * 2013-04-28 2021-02-26 无锡杰西医药股份有限公司 Combined application of isothiocyanate compounds and hormone drugs
EP3034076B1 (en) * 2013-08-13 2020-09-30 JC (Wuxi) COMPANY, Inc. Combined application of isothiocyanate compound and anti-cancer medicine
CA2923667A1 (en) 2013-09-09 2015-03-12 Triact Therapeutics, Inc. Cancer therapy
WO2017034234A1 (en) * 2015-08-21 2017-03-02 서울대학교 산학협력단 Composite formulation for treating cancer having hdac inhibitor resistance
CN108159419B (en) * 2017-12-27 2021-07-27 中国药科大学 Application of substance for inducing IRF8 expression in preparation of medicine for treating liver cancer
US20230066830A1 (en) * 2019-12-20 2023-03-02 Virginia Commonwealth University Methods and compositions for inducing apoptosis in cancer stem cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186169A1 (en) * 2001-06-19 2004-09-23 Olle Larsson Use of specific cyclolignans
WO2005111232A2 (en) * 2004-05-17 2005-11-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Silencing of tumor-suppressive genes by cpg-methylation in prostate cancer
WO2006017904A1 (en) * 2004-08-19 2006-02-23 Purdue Research Foundation Improved anticancer treatment
US20070123580A1 (en) * 2003-05-21 2007-05-31 Atadja Peter W Combination of histone deacetylase inhibitors with chemotherapeutic agents
US20070292512A1 (en) * 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186169A1 (en) * 2001-06-19 2004-09-23 Olle Larsson Use of specific cyclolignans
US20070123580A1 (en) * 2003-05-21 2007-05-31 Atadja Peter W Combination of histone deacetylase inhibitors with chemotherapeutic agents
WO2005111232A2 (en) * 2004-05-17 2005-11-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Silencing of tumor-suppressive genes by cpg-methylation in prostate cancer
WO2006017904A1 (en) * 2004-08-19 2006-02-23 Purdue Research Foundation Improved anticancer treatment
US20070292512A1 (en) * 2006-06-09 2007-12-20 Merrion Research Ii Limited Solid Oral Dosage Form Containing an Enhancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ATTARD ET AL.: "Improving the outcomes of patients with castration-resistant prostate cancer through rational drug development.", BRITISH J CANCER, vol. 95, 2006, pages 767 - 774 *

Also Published As

Publication number Publication date
WO2009108857A2 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
WO2009108857A3 (en) Combination therapy for prostate cancer
WO2008027837A3 (en) Small molecule potentiator of hormonal therapy for breast cancer
PH12017500930A1 (en) Hsp90 inhibitor combinations
WO2008076278A8 (en) Methods of cancer treatment with igf1r inhibitors
WO2008014238A3 (en) Dimeric iap inhibitors
WO2010118063A3 (en) Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
WO2011037643A3 (en) Compositions and methods for detecting and treating prostate carcinoma
MX2015006478A (en) Glutamase inhibitors and method of use.
EP2205076A4 (en) Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr ýerbb1¨and her-2 ýerbb2¨
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
SI2358697T1 (en) Isoindoline compounds for use in the treatment of cancer.
HK1159498A1 (en) Methods and compositions for the treatment of cancer
WO2008014229A3 (en) Dimeric iap inhibitors
EP2340027A4 (en) Methods and compositions for the treatment of cancer
WO2011129936A3 (en) Compositions and methods for the prevention and treatment of cancer
WO2012073047A3 (en) Compositions and methods
ZA201109513B (en) Composition for the treatment of benign prostate hyperplasia
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
WO2010141956A3 (en) Methods and compositions for the treatment of cancer
WO2011097166A9 (en) Combination therapy for treating cancer comprising an igf-1r inhibitor and an hdac inhibitor
HK1212218A1 (en) Organoarsenic compounds and methods for the treatment of cancer
WO2011056566A3 (en) Compounds and methods for treatment of cancer
WO2009126315A3 (en) Macrocyclic compounds and methods of treatment
WO2009108755A3 (en) Pharmaceutical combinations for the treatment of cancer
WO2011101634A3 (en) Methods of prevention or treatment of triggered inflammatory reactions using tumor necrosis factor alpha antagonist

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09714382

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09714382

Country of ref document: EP

Kind code of ref document: A2